The global Chloangiocarcinoma therapeutics market is expected to garner a market value of USD 800 Million in 2023 and is expected to accumulate a market value of USD 975.20 Million by registering a CAGR of 2% in the forecast period 2023 to 2033. The growth of the Chloangiocarcinoma therapeutics market can be attributed to changes in bile duct anatomy due to inflammatory bowel disease, and exposure to certain toxins and pollutants. The market for Chloangiocarcinoma therapeutics registered a CAGR of 1% in the historical period 2018 to 2022.
Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect your liver to your gallbladder and to your small intestine. Cholangiocarcinoma (CCA) tumors can arise from anywhere in the biliary tract and may be difficult to identify based on histopathologic analysis alone. CCA can be anatomically differentiated into intrahepatic CCA (ICC) and extrahepatic CCA (ECC).
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 800 Million |
| Anticipated Forecast Value (2033) | USD 975.20 Million |
| Projected Growth Rate (2023 to 2033) | 2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights,- the market for Chloangiocarcinoma (CCA) Therapeutics reflected a value of 1% during the historical period, 2018 to 2022.
In the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 46,466 which is expected to grow during the study period, i.e., 2023 to 2032. The future prospects of therapeutics for cholangiocarcinoma (CCA) are promising, but there are still many challenges to overcome. One promising area of research is the development of targeted therapies that inhibit specific molecules involved in the growth and spread of cancer cells. These therapies have shown promise in early clinical trials and are considered a promising approach to treating CCA.
Thus, the market for Chloangiocarcinoma (CCA) therapeutics is expected to register a CAGR of 2% in the forecast period 2023 to 2033.
Research and development activities shaping the landscape for Chloangiocarcinoma (CCA) therapeutics market
Early research on the genetic pathophysiology of CCAs concentrated on determining the carcinogenic function of certain genes, which were frequently discovered to be mutated in other cancers or altered by copy number changes. Studies have demonstrated that the genetic profiles of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma are diverse; in fact, 50% of patients have actionable mutations such as FGFR, IDH1, HER2, and BRAF.
For a definitive Cholangiocarcinoma diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and procedures such as cytology, brushing, FISH (fluorescence in situ hybridization)-polysomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography or 18FDG PET-CT cannot definitively demonstrate the stricture’s neoplastic nature.
Cholangiocarcinoma Treatment - Surgical resection gaining prominence owing to its promising and definitive results
Unfortunately, the outlook is bleak. Most patients have an advanced or incurable illness when they are diagnosed, leaving systemic therapy as their sole choice for treatment. It is generally known that subgroups vary in their tumor biology and clinical presentation in addition to their varied etiological sources. Surgery may be curative for individuals with resectable illness when they first arrive, although these patients make up a small percentage with substantial recurrence rates. Additionally, the recurrence patterns often prohibit additional curative resection.
The best method for extending survival is still total surgical resection (R0); however, disease recurrence is not unheard of. Furthermore, patient comorbidities sometimes precluded surgical intervention, even if it could technically be done. Therefore, in order to increase survival in such a population, reduced morbidity interventional procedures must be developed.
Surgery with complete resection represents the only treatment for CCA with curative intent. Other treatment approaches may include liver transplantation which is associated with rapid tumor recurrence and low survival, and it has historically not been recommended as a treatment for unresectable CCA. Chemotherapy for patients presenting with unresectable or metastatic CCA, systemic chemotherapy remains the mainstay palliative treatment modality, and the role of adjuvant chemotherapy is not clearly defined in CCA, but for patients with local recurrence after resectioning pCCA, chemotherapy has been recommended.
Principal Consultant
The rarity of diseases creates a lack of awareness and treatment options for the CCA therapeutics market
CCA is a rare and complex cancer, and there is still much that researchers do not know about its biology and underlying causes. This makes it difficult to develop targeted treatments. In addition, the lack of biomarkers for CCA is making it difficult to select the most appropriate treatment for an individual patient.
The limited efficacy of current treatments that include radiation therapy and chemotherapy are creating obstacles for the market. Many of the treatments currently available for CCA can have significant side effects, which can make it difficult for patients to tolerate them.
Due to the rarity of the disease, there are relatively few clinical trials for CCA, which makes it difficult to develop new treatments. The high cost of treatment for CCA can make it difficult for some patients to afford the care they need. Lastly, the lack of standard of care for CCA makes it difficult to choose the right combination of therapy.
Ongoing clinical trials creating lucrative opportunities for Chloangiocarcinoma (CCA) Therapeutics in North America
The total diagnosed incident cases of Cholangiocarcinoma were 10,034 in the USA which is expected to grow during the study period, i.e., 2023 to 2033. In North America, the treatment options for cholangiocarcinoma (CCA) include surgery, radiation therapy, chemotherapy, and targeted therapy.
Increasing research and development activities along with the presence of improved healthcare infrastructure is driving the growth of the cholangiocarcinoma therapeutics market. There are also a few clinical trials ongoing in North America to evaluate new treatments for CCA such as new combinations of chemotherapy, radiation therapy, and targeted therapy, as well as new immunotherapies. Thus, North America is expected to possess a 40% market share of the cholangiocarcinoma therapeutics market in 2023.
Focus on offering targeted therapy for Chloangiocarcinoma increasing in Asia Pacific
In the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 16,004 in Japan which is expected to grow during the study period, i.e., 2023 to 2033. Healthcare infrastructures in the Asia Pacific are focusing on offering targeted therapy that uses drugs that target specific molecules involved in the growth and spread of cancer cells. There are a few targeted therapy drugs that have been approved for use in CCA such as gemcitabine-erlotinib, capecitabine-cisplatin, and others.
In China and India, CCA is a relatively common cancer, and the incidence of the disease is increasing in both countries. The increasing incidence of CCA in China and India is contributing to the growth of more research on the causes, early detection, and treatment of the disease in these populations. Thus, Asia Pacific is expected to hold a 35% market share of Chloangiocarcinoma (CCA) therapeutics market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The convenience of buying from retail pharmacies boosting the growth of Chloangiocarcinoma (CCA) therapeutics
The growing availability of both prescription and over-the-counter drugs in retail pharmacies is driving the growth of the Chloangiocarcinoma (CCA) therapeutics market and is expected to continue in the future.
The convenience of being able to fill multiple prescriptions and purchase other healthcare products all in one place is likely a major factor in the growing popularity of retail pharmacies. It is forecasted that retail pharmacies will hold a 40% market share in the Chloangiocarcinoma (CCA) therapeutics market by 2023.
Key players in the Chloangiocarcinoma therapeutics market are AstraZeneca, Decalth Systems, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals and Servier Pharmaceuticals
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 800 Million |
| Market Value in 2033 | USD 975.20 Million |
| Growth Rate | CAGR of 2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC Countries, South Africa |
| Key Companies Profiled | AstraZeneca; Decalth Systems; Basilea Pharmaceutica; Taiho Oncology; Eisai Pharmaceuticals; TransThera Sciences; Incyte Corporation; Roche; Agios Pharmaceuticals; Servier Pharmaceuticals |
| Customization | Available Upon Request |
Ongoing clinical trails are fueling the demand in the United States.
Rising incidence of chloangiocarcinma is upsurging Europe market.
The focus on targeted therapy has necessitated chloangiocarcinma therapeutics.
North America hold a share of 40% of the global market by 2033.
North America to witness a lucrative growth opportunities through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Chemotherapy 5.1.1. Gemcitabine 5.1.2. Cisplatin 5.1.3. Oxaliplatin 5.1.4. Capecitabine 5.1.5. 5 fluorouracil (5-FU) 5.2. Targeted Therapy 5.2.1. Pemigatinib 5.2.2. Infigratinib (Phase 3) 5.2.3. Ivosidenib (Phase 3) 5.3. Immunotherapy 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Hospital Pharmacies 6.2. Retail Pharmacies 6.3. Online Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. AstraZeneca 17.2. Decalth Systems 17.3. Basilea Pharmaceutica 17.4. Taiho Oncology 17.5. Eisai Pharmaceuticals 17.6. TransThera Sciences 17.7. Incyte Corporation 17.8. Roche 17.9. Agios Pharmaceuticals 17.10. Servier Pharmaceuticals 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Chloangiocarcinoma (CCA) Therapeutics Market
